Abstract
The aim of the present study was to determine whether the attenuation of myocardial ischemic injury by SB203580 is due to the inhibition of p38 mitogen-activated protein kinase (MAPK) or to other documented nonspecific effects of the drug. We made adenoviral vectors encoding the α isoform of p38 MAPK with or without site-directed mutations to prevent SB203580 binding and inhibition. In embryonal rat heart-derived cells and adult rat cardiocytes expressing wild-type p38α MAPK, injury was reduced significantly by SB203580 present during simulated ischemia. In contrast, SB203580 did not protect cells expressing the SB203580-resistant form of p38α MAPK. These observations suggest that SB203580-mediated protection depends on the inhibition of p38α MAPK.
Original language | English |
---|---|
Pages (from-to) | 750-752 |
Number of pages | 3 |
Journal | Circulation Research |
Volume | 89 |
Issue number | 9 |
DOIs | |
Publication status | Published - 26 Oct 2001 |
Keywords
- Isolated cells
- p38 mitogen-activated protein kinase
- Preconditioning
- SB203580
- Signaling
ASJC Scopus subject areas
- Physiology
- Cardiology and Cardiovascular Medicine